Merck says new Mavenclad data show reduction in neuronal injury

German life sciences and pharma firm Merck KGaA (MRK: DE) today announced the presentation of new analyses from the Mavenclad (cladribine) MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis (RMS) experienced sustained reduction in serum neurofilament light chain (NfL), indicating that Mavenclad reduced neuronal injury over two years.

Mavenclad, which was approved in the European Union in 2017 and in the USA in 2019, is one of Merck’s best-selling products, bringing in second-quarter 2023 revenues of 262 million euros ($276 million).

Merck noted that additional data include two real-world evidence (RWE) studies, which indicated an increase in the use of cladribine tablets in treatment-naïve patients and demonstrated low levels of switching to other disease-modifying therapies (DMTs) up to four years. These data were presented at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan, Italy.